Sanofi (SNY) Gains from Investment Securities (2016 - 2026)

Sanofi has disclosed Gains from Investment Securities across 11 years of filings, most recently posting -$83.7 million for Q2 2026.

• In Q2 2026, Gains from Investment Securities fell 42.18% year-over-year to -$83.7 million; the TTM figure through Jun 2026 stood at -$300.6 million (down 67.25% YoY), while the FY2025 annual figure was -$121.1 million, down 16.51% from the prior year.
• Gains from Investment Securities came in at -$83.7 million for Q2 2026 at Sanofi, down from $41.0 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $41.0 million in Q1 2026 to a low of -$136.8 million in Q3 2025.
• Average Gains from Investment Securities over 5 years is -$36.3 million, with a median of -$14.0 million recorded in 2023.
• Year-over-year, Gains from Investment Securities tumbled 1456.83% in 2025 and jumped 532.83% in 2026.
• Over 5 years, Gains from Investment Securities stood at $15.3 million in 2022, then sank by 753.84% to -$100.1 million in 2023, then fell by 2.52% to -$102.6 million in 2024, then retreated by 18.01% to -$121.1 million in 2025, then soared by 30.87% to -$83.7 million in 2026.
• Per Business Quant data, the three most recent Gains from Investment Securities figures were -$83.7 million in Q2 2026, $41.0 million in Q1 2026, and -$121.1 million in Q4 2025.